SURVODATIDE 10mg

Price range: R1 900,00 through R2 100,00

Survodutide

What it is: Survodutide is an investigational once-weekly injectable dual glucagon receptor (GCGR) and GLP-1 receptor agonist. It is designed to combine GLP-1-mediated appetite and glucose effects with glucagon-mediated effects on energy expenditure and metabolism.
Commonly studied/marketed for: Weight loss, obesity management, improved metabolic health, and treatment of metabolic dysfunction–associated steatohepatitis (MASH).
How it works: GLP-1 receptor activation helps regulate appetite, food intake, and blood glucose, while glucagon receptor activation can increase energy expenditure and influence lipid metabolism.
Evidence: Strong and rapidly developing human clinical evidence. In a 2026 Phase 3 obesity trial, survodutide produced mean weight reductions of 12.2% and 13.0% at 76 weeks at the 3.6-mg and 6.0-mg doses, respectively, versus 5.4% with placebo. A separate Phase 3 trial in people with obesity and type 2 diabetes also demonstrated significantly greater weight loss than placebo. Earlier Phase 2 research also showed promising improvements in MASH and liver fat.
Key risks/side effects: Gastrointestinal effects are the main reported issue, including nausea, diarrhoea and vomiting. In the Phase 3 obesity trial, GI adverse events occurred in approximately 81–90% of participants receiving survodutide, compared with 48% with placebo.
Regulatory status: Survodutide remains an investigational drug rather than an established approved treatment. Its Phase 3 development is being conducted by Boehringer Ingelheim.
Bottom line: Survodutide is a next-generation metabolic drug with substantial human clinical evidence, particularly for weight reduction, and it is also being investigated for liver disease. Its dual GLP-1/glucagon mechanism makes it distinct from single-pathway GLP-1 drugs, but it should still be regarded as investigational until regulatory approval is granted.

Description

SURVODATIDE – ADVANCED METABOLIC & WEIGHT-MANAGEMENT RESEARCH PEPTIDE

Elevate Wellness Hub’s Survodutide is an investigational dual GLP-1 and glucagon receptor agonist being studied for its effects on body weight, appetite regulation, glucose metabolism, energy expenditure, and liver health.

KEY BENEFITS

Supports research into appetite and metabolic regulation
Investigated for body-weight management
Supports research into glucose metabolism
Investigated for effects on energy expenditure
Studied in relation to liver fat and metabolic liver disease
Supports research into GLP-1 and glucagon signalling

WHO MAY BENEFIT?

Individuals being medically evaluated for obesity or metabolic disease, Those interested in research into appetite and metabolic pathways, Individuals studying metabolic dysfunction-associated liver disease, People exploring investigational approaches to weight and metabolic health.

Always use under the guidance of a qualified healthcare professional.

HOW IT MAY HELP

Survodutide activates both GLP-1 and glucagon receptors
GLP-1 receptor activity can influence appetite, food intake, and glucose regulation
Glucagon receptor activity may influence energy expenditure and hepatic metabolism
Clinical trials have investigated Survodutide for obesity and metabolic liver disease
Research has shown reductions in body weight and improvements in measures of liver fat in clinical studies
Survodutide remains investigational, and its long-term safety and full clinical role are still being evaluated

POSSIBLE SIDE EFFECTS

Potential adverse effects may include:

Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort
Reduced appetite
Indigestion
Headache
Fatigue
Dizziness
Injection-site reactions
Potential changes in blood-glucose levels
Potential gallbladder-related complications

Gastrointestinal adverse effects are particularly relevant to GLP-1–based therapies.

NOT SUITABLE FOR

Pregnancy or breastfeeding
Anyone with a known allergy or sensitivity to Survodutide or any ingredient
Children unless specifically prescribed and supervised by an appropriate specialist
Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
Individuals with MEN2 syndrome
Individuals with significant gastrointestinal disease without appropriate medical assessment
Individuals with a history of pancreatitis without specialist assessment
Anyone with significant gallbladder, liver, kidney, or endocrine disease without appropriate healthcare supervision
Anyone taking other GLP-1 receptor agonists or metabolic medications without professional guidance

IMPORTANT DISCLAIMER

Survodutide is an investigational dual GLP-1/glucagon receptor agonist and is not the same medication as semaglutide or tirzepatide.

Clinical research has investigated Survodutide for obesity, metabolic health, and metabolic dysfunction-associated steatotic liver disease, with promising results reported in clinical trials. However, it has not been established as a generally approved weight-loss or liver-disease treatment in all jurisdictions, and long-term safety remains under investigation.

Elevate Wellness Hub does not represent Survodutide as a substitute for approved medical treatment. Any use must comply with applicable laws and regulations and should only occur under appropriate qualified healthcare-professional supervision or within an authorised clinical-research setting.

The 10 mg listed by Elevate Wellness Hub refers to the product strength and is not a dosing recommendation.

It’s not just about feeling better, it’s about elevating your quality of life.

ELEVATE WELLNESS HUB – PEPTIDE WELLNESS. SCIENCE BACKED. RESULTS DRIVEN. YOU ELEVATED.

Additional information

Weight	N/A
Type	VIAL, PEN

Reviews

There are no reviews yet.

Be the first to review “SURVODATIDE 10mg”